Epigenetic and fragment-based profiling across CDK4/6 inhibitors in first-line HR+/HER2– metastatic breast cancer. An ancillary analysis of the MAGNETIC.1 study

Key Points

• Molecular dynamics reveal treatment-specific differences between CDK4/6 inhibitors in breast cancer therapy.
• The study utilized ctDNA-based methylation and fragmentomic profiling to assess biological responses.
• Observational analysis using liquid biopsy-based biomarkers showed potential for clinical relevance.
• Preliminary findings highlight the need for further validation in larger cohorts with more detail on treatment timing.

Abstract